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ABSTRACT Regions of the hamster a1-adrenergic recep-
tor (aAR) that are important in GTP-binding protein (G
protein)-mediated activation of phospholipase C were deter-
mined by studying the biological functions of mutant receptors
constructed by recombinant DNA techniques. A chimeric
receptor consisting of the P2-adrenergic receptor (j2AR) into
which the putative third cytoplasmic loop of the ajAR had been
placed activated phosphatidylinositol metabolism as effectively
as the native ajAR, as did a truncated a1AR lacking the last 47
residues in its cytoplasmic tail. Substitutions of 12AR amino
acid sequence in the intermediate portions of the third cyto-
plasmic loop of the ajAR or at the N-terminal portion of the
cytoplasmic tail caused marked decreases in receptor coupling
to phospholipase C. Conservative substitutions of two residues
in the C terminus of the third cytoplasmic loop (Ala23 -> Leu,
Lys2' --0His) increased the potency of agonists for stimulating
phosphatidylinositol metabolism by up to 2 orders of magni-
tude. These data indicate (T) that the regions of the ajAR that
determine coupling to phosphatidylinositol metabolism are
similar to those previously shown to be involved in coupling of
(3AR to adenylate cyclase stimulation and (is) that point
mutations of a G-protein-coupled receptor can cause remark-
able increases in sensitivity of biological response.
The adrenergic receptors (AR) (a,, a2, 181, /32, 3) mediate the
physiological effects of epinephrine and norepinephrine via
intermediacy of GTP-binding proteins (G proteins), each of
which modulates a distinct intracellular effector system. The
molecular cloning ofthe genes and/or cDNAs ofthe AR (1-7)
as well as of several other G-protein-coupled receptors (8-12)
has revealed that these proteins share a common topograph-
ical motif consisting of seven putative transmembrane re-
gions joined by intracellular and extracellular loops. Knowl-
edge of the primary structure of several G-protein-coupled
receptors has allowed the investigation of the structural basis
for different receptor functions, in particular, ligand binding
and receptor coupling to distinct G proteins. Studies with
chimeric a2/,32AR have indicated that the specificity ofp2AR
coupling to adenylate cyclase stimulation via the Gs protein
lies in the region including the third intracellular loop (13).
Mutagenesis studies by amino acid deletion or substitution of
the third intracellular loop of the 182AR have also indicated
that this cytoplasmic region is critical for productive coupling
of the f2AR to Gs (14-16). Despite the amount of information
existing about the structural basis for f32AR coupling to GU,
very little is known about the structural domains involved in
the coupling ofother receptors to different G protein-effector
systems. Studies with chimeric muscarinic cholinergic re-
ceptors (MAchR) have indicated that a region mainly com-
prising the putative third intracellular loop is involved in
selective coupling of M1- and M2AchR to their respective
effector systems (17).
We have previously shown that the a1AR cloned from
DDT1MF-2 smooth muscle cells stimulates phosphatidylino-
sitol (PI) hydrolysis catalyzed by phospholipase C (PLC) via
an as yet uncharacterized G protein (1). In this study, we have
investigated the role of the putative intracellular domains of
the ajAR in mediating its coupling to PLC by constructing a
variety of chimeric, truncated, and site-directed mutant
a1AR. The mutants were expressed in COS-7 cells and tested
for their abilities to bind adrenergic ligands and to activate PI
metabolism. Our results identify the regions in the cytoplas-
mic domains of the ajAR that are most critically involved in
coupling to G-protein-mediated activation of PLC.
EXPERIMENTAL PROCEDURES
Plasmids. For the construction of chimeric 132/aiAR, res-
idues 228-295 of the hamster a1AR (1) were substituted for
residues 224-274 of the human fi2AR (6) by splicing the
desired restriction fragments ofDNA encoding the wild-type
receptors with synthetic oligonucleotide adapters. For
expression studies, the f32AR and chimeric P2/aAR were
subcloned into the expression vector pBC12BI (18) as de-
scribed (19). For construction of the ajAR mutants, single-
stranded DNA was prepared from pTZ18R (Pharmacia) con-
taining the cDNA of the a1AR and used for oligonucleotide-
directed mutagenesis (Amersham). The identity of each
mutant was confirmed by dideoxy sequencing of single- and
double-stranded DNA with Sequenase (United States Bio-
chemical). For expression studies, the expression vector
pBCa1 (19) was digested with Xho I and Apa I and ligated to
the Xho I-Apa I restriction fragments of each mutated ajAR
species to obtain pBC12BI plasmids containing the DNA for
each mutated receptor.
Mammalian Cell Expression. COS-7 cells were grown in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with gentamicin (100 ,ug/ml) and 10%o fetal bovine
serum (GIBCO). COS-7 cells were transfected by the DEAE-
dextran method (18) with pBC12B1 containing the DNA of
different receptor species, using 2 tug of DNA per 5 x 105
cells. Cells were harvested 48 hr after transfection.
Ligand Binding. Membrane preparation and ligand binding
with 2-{J3-(4-hydroxy-3-[1251]iodophenyl)ethylaminomethyl}-
tetralone ([1251]HEAT) for ajAR and [125I]iodocyanopindolol([125I]ICYP) (DuPont-New England Nuclear) for f2AR bind-
ing were performed using 1 ,M prazosin and 1 ,uM alprenolol
to determine nonspecific binding, respectively (15, 19). For
saturation binding analysis, [1251]HEAT and [ 25I]ICYP con-
Abbreviations: AR, adrenergic receptor(s); G protein, GTP-binding
protein; PI, phosphatidylinositol; aa, amino acid(s); PLChspho-
lipase C; MAchR, muscarinic cholinergic receptor(s); [ IOHEAT,
2-To-(4-hydroxy-3-[mIriodophenyl)ethylaminomethyldtetralone;[125I]ICyp, [1251]iodocyanopindolol.
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centrations ranged from 10 to 500 pM. Agonist competition
binding experiments used 100 pM radioligand. Data were
analyzed by nonlinear least-squares regression (20).
Inositol Phosphate Determination. Cells were labeled with
[3H]inositol (DuPont-New England Nuclear) at 3 ,Ci/ml (1
,uCi = 37 kBq) in DMEM supplemented with 3% fetal bovine
serum. After labeling, cells were washed and incubated in
phosphate-buffered saline for 30 min, followed by a 30-min
incubation in phosphate-buffered saline with 20 mM LiCI.
Inositol phosphates were extracted (21) and separated on AG
1-X8 columns (22). Total inositol phosphates were eluted
with 1 M ammonium formate/0.1 M formic acid.
RESULTS
Previous studies of the ,82AR have indicated that the putative
third cytoplasmic loop is crucial in determining coupling to G,
and that much of the C-terminal tail is not required for
coupling. To assess whether these properties might be com-
mon to other members of the G-protein-coupled receptor
family, we examined the potential involvement of these
structural domains in coupling of the a1AR to PI hydrolysis.
Initially, two constructs were made. In the first, we con-
structed a truncated a1AR (T368) by inserting a stop codon
after Arg368 (Fig. 1, Table 1), thus deleting most of the
cytoplasmic tail of the receptor. With T368, the efficacy
(Rma,,) and potency (EC50) of norepinephrine for stimulating
PI turnover, as well as the ligand-binding properties, were
similar to those of the wild-type receptor (Table 1). This
indicates that the C terminus ofthe ajAR beyond Arg368 is not
required for either ligand binding or effector activation, in
agreement with the results obtained with the I32AR (16).
In the second mutant, we created a chimeric 182/aAR in
which the entire third intracellular loop of the human f82AR
was replaced with the corresponding region of the hamster
ajAR (Fig. 1). When the P2AR, chimeric 82/aAR, and ajAR
were expressed in COS-7 cells prelabeled with [3HJinositol,
epinephrine was able to stimulate release, of inositol phos-
phates in cells expressing /82/aAR or ajAR but not in cells
expressing p82AR (Fig. 2). The effect of epinephrine on
f32/aAR was completely blocked by propranolol (10 ,uM),
whereas its effect was abolished by prazosin (10 ,uM) in cells
expressing a1AR (data not shown). The relative order of
potency of agonists for inositol phosphate release mediated
by 82/aAR are in agreement with those for adenylate
cyclase stimulation in cells expressing p2AR (23) (EC50
values of isoproterenol, epinephrine, and norepinephrine
were 0.14, 0.73, and 10 AtM for,82/aAR and 300, 1.2, and 2.2
AM for ajAR, respectively). Ligand binding studies showed
that the P2/ajAR specifically bound the BAR antagonist
[125I]ICYP with affinity similar to that of the wild-type
receptor (Kd values were 30 and 53 pM for 82/aAR and
32AR, respectively). However, the expression level of .32/
ajAR was lower than that of 82AR (Bm|a values were 5.5 and
17.5 pmol/mg of membrane protein for 32/a1AR and .32AR,
respectively). Interestingly, the Ki values of isoproterenol,
epinephrine, and norepinephrine for 32/a1AR (0.03, 0.19, and
2 ,uM, respectively) were 10-fold lower than for the 132AR
(0.29, 1.62, and 27 ,uM, respectively). These data confirm the
chimeric nature of the .2/a1AR, which binds ligands with the
classical specificity of the 32AR but which demonstrates the
effector function of an ajAR. These data also clearly dem-
onstrate that the third cytoplasmic loop of a1AR confers on
132AR the ability to activate PLC.
To further explore which sequences within the putative
third intracellular loop of the ajAR are critical for coupling to
PI hydrolysis, we mutagenized selected residues within this
loop. Alignment of the amino acid sequence of the third
intracellular loop of the ajAR with the corresponding se-
quences of other G-protein-coupled receptors reveals that
these receptors share striking homology in the N- and C-
terminal portions of this domain. Besides these two portions,
we identified additional regions of less striking, but still
significant, homology in the third intracellular loops of the
ajAR, p2AR, and MAchR: amino acids (aa) 242-250 of the
ajAR (MKEMSNSKE) and aa 279-287 of the M2AchR(EKESSNDST) (11); aa 252-259 of the ajAR (TLRIHSKN)
E H TRA C E L L U L BR
FIG. 1. Seven transmembrane-domain model of the a1AR. The circumscribed area shows the portion of the putative third intracellular loop
that was incorporated in the 82AR to construct the chimeric f82/aAR. Boxed sequences indicate the specific amino acids that were replaced
in the various mutants with the corresponding sequences of the P2AR shown in Table 1. The numbers refer to amino acid positions, and "stop"
indicates the position where a stop codon was introduced to construct the truncated ajAR T368. Solid circles indicate amino acids common
to the corresponding position in the /82AR in the regions that have been mutagenized. Potential asparagine-linked glycosylation sites near the
N terminus are shown as crosses.
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Table 1. Parameters of ligand binding and activation of PI metabolism obtained with mutant a1AR
Ligand bindingt NE-stimulated PI
NE [[1251]HEAT hydrolysist
Kiq Kd, Bmax, Rmax, EC50.
Receptor Substitution* JmpM pmol/mg % increase M
a1AR 15.5 68 5.7 232 3.5
S227-229 YIV - FQE 1.6 79 3.3 127 2.9
S242-250 MKEMSNSKE - LQKIDKSEG 8.5 90 3.4 127 7.5
S252-259 TLRIHSKN EGRFHVQN 12.3 79 6.0 20
S262-267 EDTLSS QVEQDG 10.7 60 4.8 156 1.5
S288-294 REKKAAK - KEHKALK 0.08 53 1.4 245 0.01
S288 R-K 9.6 65 5.5 231 2.8
S290 K H 0.88 55 3.5 218 0.07
S293 A-- L 0.20 50 1.6 200 0.02
S353-365 KEFKRAFMRILGE 10 80 5.7 138 5.9
PDFRIAFQELL-C
T368 5.5 63 6.0 250 3
*The locations of the a1AR sequences that were replaced are indicated in Fig. 1.
t[1251]HEAT and norepinephrine (NE) binding. were measured as described under Experimental Procedures.
tCOS-7 cells (106) expressing the various receptors were stimulated with various concentrations of NE for 30 min. Rmax indicates the percentage
increase of inositol phosphates over basal induced by 100 AM NE. The results are the means of two to six independent experiments each
performed in triplicate, which agreed within 20o.
and aa 237-244 of the ,32AR (EGRFHVQN) (6); and aa
262-267 of the a1AR (EDTLSS) and aa 294-299 of the
MjAchR (EEPGSE) (11). We reasoned that these conserved
sequences in the third intracellular loop might be involved in
overall receptor-G protein interactions. On the other hand,
the residues that differ between the a1AR and other receptors
in these conserved regions might be responsible for the
specificity of a1AR coupling to its G protein.
To test this hypothesis, we investigated whether replace-
ment of these portions of the third intracellular loop of the
ajAR with corresponding sequences derived from the P2AR
could affect the functional properties of the resulting recep-
tor. Table 1 shows that all the mutant receptors bound
[125I]HEAT with similar affinity as the a1AR. Mutants S227-
229 and S242-250, with modified sequences in the N-terminal
portion of the third intracellular loop of the a1AR, exhibited
a decrease both in receptor expression levels and in the
efficacy (Rma) of norepinephrine to promote release of
inositol phosphates. The K1 and EC50 values of norepineph-
rine were similar between S242-250 and ajAR. Interestingly,
S227-229 displayed a 10-fold higher affinity for norepineph-
rine, but without a corresponding change in its potency to
activate PI hydrolysis. Since the ligand-binding properties of
O BAS
32 _ MEP (I100M)
24-
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FIG. 2. Inositol phosphate release in COS-7 cells expressing
f32AR, a1AR, and chimeric f32/aAR. Total inositol phosphates were
measured after a 30-min incubation in the presence of vehicle (basal,
BAS) or 100AM epinephrine (EPI). The receptor density was 15, 6.0,
and 3.8 pmol/mg of membrane protein for 12AR, ajAR, and P2/
ajAR, respectively. The results are means + SEM of three inde-
pendent experiments each performed in triplicate.
these mutant receptors were comparable to those of the
a1AR, the decreased expression may reflect an impairment of
processing, insertion, and/or folding of the receptor protein
in the plasma membrane. These results are in agreement with
previous findings showing that the regions of the third
intracellular loop of the 162AR that are adjacent to the
membrane are important for normal receptor expression (24).
A previous study has shown that an a1AR-mediated increase
of PI metabolism is highly dependent on the receptor number
expressed in COS-7 cells (19). These observations suggest
that the reduction of norepinephrine's efficacy to release
inositol phosphates observed with S227-229 and S242-250
may be the result of depressed receptor expression. There-
fore, the N-terminal portion of the third intracellular loop of
the a1AR does not seem to be critical for the specificity of
receptor coupling to PLC, as previously proposed for 82AR
(15).
Substitution of aa 252-259 and 262-267 in the intermediate
portion of the third intracellular loop of a1AR did not affect
receptor expression (Table 1). These substitutions, however,
resulted in 90% and 32% impairment in the ability of norepi-
nephrine to activate PI hydrolysis, respectively. The de-
crease in the efficacy of norepinephrine to activate PI me-
tabolism was not accompanied by a detectable change in its
potency and/or binding affinity. That replacement of aa
252-259 almost completely abolished a1AR-mediated activa-
tion of PI metabolism suggests a prominent role of these
residues in the interaction between the a1AR and its G
protein-effector system.
In addition to the third cytoplasmic loop, the N-terminal
portion of the cytoplasmic tail of the P2AR has also been
shown to be implicated in the coupling of the ,B2AR to Gs (15,
16). Therefore, we investigated the role of this region in a1AR
coupling to PLC activation by replacing aa 353-365 of the
a1AR with the corresponding residues of the f32AR. This
substitution resulted in 40% impairment of the ability of the
a1AR to activate PI metabolism, without any significant
change in receptor expression level and the affinity or po-
tency of norepinephrine. As previously shown for f32AR
coupling to Gs (15, 16), these results suggest that the N-
terminal segment of the cytoplasmic tail of the a1AR is
important for productive coupling of the a1AR to PLC.
In contrast to substitution mutations that resulted in an
impairment of a1AR function, a conservative substitution for
aa 288-294 at the C terminus of the third intracellular loop
Proc. Natl. Acad. Sci. USA 87 (1990)
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resulted in a dramatic change in the properties of the ex-
pressed receptor. The mutant receptor showed a 100-fold
higher affinity for norepinephrine and a 300-fold higher
potency of norepinephrine to activate PI metabolism. The
coupling efficacy of S288-294 to PLC was even greater than
for the native receptor, since the amount of mutant receptor
expressed was only 25% that of the wild-type receptor.
Since substitution of aa 288-294 resulted in the conserva-
tive modification of only three residues (Arg', Lys', and
Ala"3), we investigated which of these residues was specif-
ically responsible for the functional modifications observed
with S288-294. Thus, we individually replaced Arg"8,
Lys290, or Ala293 with the corresponding residue of the P2AR.
An Arg288 -- Lys mutation did not modify the ligand-binding
or functional properties of the a1AR (Table 1). On the other
hand, both an Ala293 -+ Leu and a Lys' -+ His mutation
increased the affinity and potency of norepinephrine (Table
1; Fig. 3) with the Ala293 -* Leu substitution being the most
effective. Although expression of the S293 and S290 mutant
receptors was, respectively, 70%o and 40%6 lower than that of
the a1AR, the maximal stimulation of PI metabolism was
comparable to that of the wild-type receptor.
The observation that replacement of Ala 93 or Lys2' spe-
cifically affected agonist, but not antagonist, binding and
increased both the potency and efficacy of norepinephrine for
stimulating PI metabolism suggests a direct involvement ofthe
C-terminal portion of the third intracellular loop of the aiAR
in receptor-G protein interactions. Interestingly, the basal
level of inositol phosphates in COS-7 cells expressing S288-
294 was twice as high as in cells expressing ajAR (Fig. 4).
Similarly, a 40%o increase in inositol phosphates was observed
in COS-7 cells expressing S293 and S290, but not in cells
expressing S288 (Fig. 4). The inositol phosphate content of
cells expressing either the wild-type or mutant ajAR did not
differ from that of nontransfected cells (data not shown).
Because of the extraordinarily high affinity ofS288-294 for
norepinephrine, we investigated whether the increased inosi-
tol phosphate content of COS-7 cells expressing S288-294
receptor resulted from activation of the receptor by small
amounts ofcatecholamines that may have been present in the
cell growth medium. To test this hypothesis, cells were
deprived of serum for 24 hr prior to transfection, which was
also performed in the absence of serum. After transfection,
cells were labeled for 24 hr with [3H]inositol in medium
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without serum. Following this treatment, COS-7 cells ex-
pressing S288-294 still exhibited a 50-100% increase in
inositol phosphates as compared to cells expressing the ajAR
(data not shown). Only when cells expressing S288-294 were
grown in the presence of the aAR antagonist prazosin (10
,uM) or phentolamine (100 ,uM) did the levels of inositol
phosphates observed in the absence of agonist approximate
those in the cells expressing the a1AR (data not shown).
These results might indicate that serum deprivation for 48 hr
did not deplete the cells of endogenous catecholamines.
Thus, minute amounts of catecholamines present in the
growth medium, which would ordinarily not be sufficient to
activate the a1AR, can stimulate S288-294 due to its extraor-
dinarily high affinity for the agonist. This effect can be
blocked by the antagonist. Alternatively, our findings might
indicate that S288-294 is constitutively active. Replacement
of Ala13 with leucine and Lys290 with histidine might favor
the active (i.e., agonist-bound) conformation of the receptor,
resulting in its productive coupling to PLC even in the
absence of added agonist. In this model antagonists would
prevent constitutive receptor-G protein coupling by stabiliz-
ing an inactive conformation of the receptor.
DISCUSSION
By constructing a chimeric 32/aAR, we have demonstrated
that the third intracellular loop of the a1AR is able to confer
on the ,82AR the ability to activate PI hydrolysis. This finding
extends the notion, previously shown for the P2AR and the
M1- and M2AchR, that the putative third intracellular loop
comprises the most important determinants for receptor
coupling to its specific G protein. By replacing a1AR se-
quences in the cytoplasmic regions with corresponding se-
quences of the f32AR, we have established that sequences in
the intermediate and C-terminal portions of the loop, as well
as in the N-terminal segment of the cytoplasmic tail, are
important for coupling of the a1AR to PI metabolism.
These results are in general agreement with previous
findings suggesting that the C-terminal portion of the third
intracellular loop and the N-terminal segment of the cyto-
plasmic tail ofthe 82AR form a binding surface for G, (15, 16).
Since the N- and C-terminal regions of the third cytoplasmic
loops of G-protein-coupled receptors have been predicted to
form amphipathic a-helices, the distribution of charged and
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FIG. 3. Effect of conservative substitutions in the C terminus of the third intracellular loop of the ajAR on norepinephrine binding affinity
and potency to increase inositol phosphates. (A) [125I]HEAT (100 pM) binding to COS-7 cell membranes was determined in the presence of
various concentrations of norepinephrine; 100%o bound was 10 pM for each membrane preparation. The Ki of norepinephrine was 9.5 t&M for
ajAR, 12.5 ,uM for S288, 1.15 ,uM for S290, 0.26 uM for S293, and 0.07 A.M for S288-294. (B) Total inositol phosphates were measured after
a 30-min incubation with various concentrations of norepinephrine. The 100%o maximal increase above basal did not differ significantly among
cells expressing the various receptors, and ranged from 200%o to 250%6. The EC50 of norepinephrine was 3.0 jLM for ajAR, 1.2 ,.uM for S288,
0.13 jLM for S290, 0.05 ,uM for S293, and 0.02 ,uM for S288-294. Results are representative of three independent experiments.
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FIG. 4. Increased basal inositol phosphate content in COS-7 cells
expressing mutant ajAR with conservative substitutions in the C
terminus of its third intracellular loop. Total inositol phosphates were
measured in the absence of agonist stimulation. Receptor density
(pmol/mg of membrane protein) was 6.2 for a1AR, 1.2 for S288-294,
5.5 for S288, 3.0 for S290, and 1.0 for S293. Data are means ± SEM
from three independent experiments each done in triplicate.
hydrophobic moments ofthese helices have been proposed to
determine the specificity ofreceptor-G protein coupling (16).
However, deletion of the C-terminal portion of the third
intracellular loop of the J32AR did not completely abolish
f32AR-mediated adenylate cyclase stimulation (14, 16), sug-
gesting that other regions of the receptor are involved in
coupling to Gs. In agreement with this observation is our
finding that substitution of aa 252-259 in the intermediate
portion of the third intracellular loop of the ajAR almost
completely abolished receptor-mediated activation of PI me-
tabolism. It is of further interest that aa 252-259 are con-
served in the third cytoplasmic loop of a novel a1AR subtype
that has been cloned recently (25), suggesting a role of this
sequence as a recognition site for the G proteins coupled to
the a1AR family. In addition, our results indicate that con-
servative substitutions for Ala293 and Lys21 in the C-terminal
portion of the third intracellular loop increased the affinity of
norepinephrine binding and its potency for stimulating PI
metabolism by 1-2 orders of magnitude.
Point mutations have been shown to activate several pro-
tooncogenes (26), and two single amino acid mutations con-
stitutively activate the a subunit of Gs in a subset of human
pituitary tumors (27). Our findings suggest that point muta-
tions might activate a receptor either constitutively or by
virtue of the extraordinarily high affinity of the receptor for
endogenous agonist. Thus, the receptor might respond to the
minute quantities of agonist circulating in the plasma even
though wild-type receptor does not. Modifications of a region
of the receptor implicated in G-protein coupling may represent
a fertile approach to developing mutant receptors displaying
activity even in the absence of agonist. Such mutants might not
only help to illuminate the biochemical mechanisms involved
in receptor-G protein coupling but also provide models for
how point mutations might activate potentially oncogenic
receptors (28).
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